Abstract

Sensory neuron-specific Mas-related G protein-coupled receptors-X1 (MRGPR-X1) are primate-specific proteins that are exclusively expressed in primary sensory neurons and provoke pain in humans. Hence, MRGPR-X1 represent promising targets for future pain therapy, but signaling pathways activated by MRGPR-X1 are poorly understood. The transient receptor potential cation channel V1 (TRPV1) is also expressed in primary sensory neurons and detects painful stimuli such as protons and heat. G(q)-promoted signaling has been shown to sensitize TRPV1 via protein kinase C (PKC)-dependent phosphorylation. In addition, recent studies suggested TRPV1 activation via a G(q)-mediated mechanism involving diacylglycerol (DAG) or phosphatidylinositol-4,5-bisphosphate (PIP(2)). However, it is not clear if DAG-promoted TRPV1 activation occurs independently from classic TRPV1 activation modes induced by heat and protons. Herein, we analyzed putative functional interactions between MRGPR-X1 and TRPV1 in a previously reported F11 cell line stably over-expressing MRGPR-X1. First, we found that MRGPR-X1 sensitized TRPV1 to heat and protons in a PKC-dependent manner. Second, we observed direct MRGPR-X1-mediated TRPV1 activation independent of MRGPR-X1-induced Ca(2+)-release and PKC activity or other TRPV1 affecting enzymes such as lipoxygenase, extracellular signal-regulated kinases-1/2, sarcoma, or phosphoinositide 3-kinase. Investigating several TRPV1 mutants, we observed that removal of the TRPV1 binding site for DAG and of the putative PIP(2) sensor decreased MRGPR-X1-induced TRPV1 activation by 71 and 43%, respectively. Therefore, we demonstrate dual functional interactions between MRGPR-X1 and TRPV1, resulting in PKC-dependent TRPV1 sensitization and DAG/PIP(2)-mediated activation. The molecular discrimination between TRPV1 sensitization and activation may help improve the specificity of current pain therapies.

Highlights

  • MRGPR-X1 are exclusively expressed in primary sensory neurons, provoke the sensation of pain, and are considered as promising targets for pain therapy

  • Ca Release, sarcoma kinase (SRC), phosphoinositide 3-kinase (PI3K), protein kinase D (PKD), or extracellular signal-regulated kinases-1/2 (ERK-1/2) Activity—Given that MRGPR-X1-induced activation of transient receptor potential cation channel V1 (TRPV1) does not require LOX or protein kinase C (PKC) activity, we addressed a putative role of SRC, PI3K, PKD, or ERK-1/2 in this process

  • Due to the exclusive expression in dorsal root ganglia (DRG) neurons, high affinity binding to pro-enkephalin cleavage products and their role for nociception in humans, MRGPR-X1 are considered as promising novel targets for pain therapy

Read more

Summary

Introduction

MRGPR-X1 are exclusively expressed in primary sensory neurons, provoke the sensation of pain, and are considered as promising targets for pain therapy. Results: MRGPR-X1 sensitize TRPV1 for protons and heat via PKC and directly activate TRPV1 via DAG and PIP2. The transient receptor potential cation channel V1 (TRPV1) is expressed in primary sensory neurons and detects painful stimuli such as protons and heat. Recent studies suggested TRPV1 activation via a Gq-mediated mechanism involving diacylglycerol (DAG) or phosphatidylinositol-4,5-bisphosphate (PIP2). It is not clear if DAG-promoted TRPV1 activation occurs independently from classic TRPV1 activation modes induced by heat and protons. We demonstrate dual functional interactions between MRGPR-X1 and TRPV1, resulting in PKC-dependent TRPV1 sensitization and DAG/PIP2-mediated activation. The molecular discrimination between TRPV1 sensitization and activation may help improve the specificity of current pain therapies

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call